Best Practices Forum: The role of icosapent ethyl for CV risk reduction

Details & Video

Best Practices Forum: The role of icosapent ethyl for CV risk reduction banner

Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)

Program Time: 60 minutes - This program is a recording of a live broadcast held on July 8, 2020
Accreditation-CME Credits: This program is not accredited. Physicians may earn self-learning credits through active steps. Instructions will be provided in the completion certificate. Target Audience: General practitioners and CV specialists
Target Audience: General practitioners and CV specialists

Perspectives from family practice, diabetology, and cardiology

Overview & Objectives

Best Practices Forum: The role of icosapent ethyl for CV risk reduction

Target Audience: General practitioners and CV specialists.

Perspectives from primary care,diabetology and cardiology.

Learning Objectives:

To review the role of serum triglycerides as a risk marker vs. a risk factor

To differentiate icosapent ethyl from standard fish oils

To best apply the findings from the REDUCE-IT study to clinical practice



Faculty

Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS
Brampton, ON

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

David C. W. Lau
David C. W. Lau
MD, PhD, FRCPC
Calgary, AB

Professor of Medicine,
Biochemistry & Molecular Biology
Julia McFarlane Diabetes Research Centre and
Libin Cardiovascular Institute of Alberta
University of Calgary Cumming School of Medicine

Richard Ward
Richard Ward
MD, CCFP, FCFP
Calgary, AB

Clinical Associate Professor,
University of Calgary
Medical Director, Primary Care,
Alberta Health Services

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Are serum triglycerides a risk factor?
Do fish oils reduce CV risk?
How does icosapent ethyl differ from fish oils?
What are the main results of the REDUCE-IT study?
What is the mechanism of benefit?
How should we use icosapent ethyl in our practices?


Sponsorship

CCRN sm

This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.

HLS Therapeutics | Clinical Trial Statistical Analysis, Study ...



Links & Resources

Download program slides - PDF